An evaluation of the effectiveness of Pulmicort Respules (budesonide inhalation suspension) versus Singulair (montelukast sodium) in children 2-8 years old with asthma requiring controller therapy

Trial Profile

An evaluation of the effectiveness of Pulmicort Respules (budesonide inhalation suspension) versus Singulair (montelukast sodium) in children 2-8 years old with asthma requiring controller therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2008

At a glance

  • Drugs Budesonide; Montelukast
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top